➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Moodys
Express Scripts
McKesson
AstraZeneca

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,829,186

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,829,186 protect, and when does it expire?

Patent 8,829,186 protects ZYPITAMAG and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,829,186
Title:Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof
Abstract: The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.
Inventor(s): Dwivedi; Shriprakash Dhar (Gujarat, IN), Patel; Dhimant Jasubhai (Gujarat, IN), Shah; Alpesh Pravinchandra (Gujarat, IN), Khera; Brij (Princeton, NJ)
Assignee: Cadila Healthcare Limited (Ahmedabad, IN)
Application Number:13/665,932
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Process;

Drugs Protected by US Patent 8,829,186

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Medicure ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379-001 Jul 14, 2017 DISCN Yes No   Start Trial   Start Trial Y Y   Start Trial
Medicure ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379-002 Jul 14, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Medicure ZYPITAMAG pitavastatin magnesium TABLET;ORAL 208379-003 Jul 14, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,829,186

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India159/MUM/2010Jan 20, 2010

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Baxter
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.